IMI cancer tests accepted for three presentations at upcoming medical meeting
biz.yahoo.com
New clinical results on colorectal, lung and breast cancer tests accepted for April meeting
TORONTO, Feb. 4 /CNW/ - Predictive medicine company IMI International Medical Innovations Inc. (TSX:IMI - News) announced today that three scientific abstracts featuring the company's unique cancer-screening tests have been accepted for presentation at the American Association for Cancer Research (AACR) 94th Annual Meeting, scheduled for April 5-9 in Toronto. The three abstracts contain new clinical trial data on the company's three cancer- detection products: ColorectAlert(TM) for colorectal cancer, LungAlert(TM) for lung cancer, and a new test for breast cancer.
ADVERTISEMENT
"By presenting new clinical data on all three of our cancer tests at a major international meeting we expect to generate further awareness of this promising new approach to cancer screening," said Dr. Brent Norton, IMI President and CEO. "These studies are our largest to date using the IMI tests on each of the three cancers, and continue to build the scientific foundation for the tests."
The abstracts accepted for presentation are:
Colorectal cancer
"Quantitative galactose oxidase Schiff's reactivity of rectal mucus correlates with colorectal cancer," co-authored by Dr. Norman Marcon, St. Michael's Hospital (Toronto), Dr. Sapna Syngal, Harvard University, Dr. Dean Brenner, University of Michigan Medical Center, and Dr. Michael Evelegh, IMI. (To be presented Sunday, April 6.)
Breast cancer
"Prospective evaluation of a novel quantitative galactose oxidase- Schiff's reaction in nipple aspirate fluid from women with invasive breast carcinoma," co-authored by Dr. Anees Chagpar, Dr. Herbert Fritsche, Dr. Savitri Krishnamurthy, Dr. Kelly Hunt and Dr. Henry Kuerer of University of Texas M.D. Anderson Medical Center, and Dr. Michael Evelegh of IMI. (Wednesday, April 9)
Lung cancer
"Clinical evaluation of a new screening test for lung cancer based on galactose oxidase Schiff's reactivity in sputum samples," co-authored by Dr. John Miller and Dr. Gerard Cox of St. Joseph's Hospital (Hamilton), Dr. Katherine Radford, McMaster University, and Dr. Michael Evelegh and Dr. Robert Zawydiwski of IMI. (Sunday, April 6)
Each of IMI's three cancer tests detects the same marker (N-acetyl-D galactosamine) in mucus samples taken from different parts of the body. ColorectAlert, IMI's screening test for colorectal cancer, identifies the carbohydrate marker in a sample of rectal mucus that is collected by the physician as part of a routine exam. Unlike existing tests for colorectal cancer, no dietary or other preparation is required by the patient, and patients are not required to collect the samples themselves, a feature of existing tests that reduces overall compliance.
LungAlert is IMI's non-invasive test for lung cancer that detects the marker in a sputum sample. There are currently no effective screening tests available for lung cancer despite the fact that lung cancer is by far the deadliest cancer worldwide. IMI's newest cancer test for breast cancer identifies the same carbohydrate marker in a sample of breast nipple aspirate. Nipple aspirates are small amounts of fluid from the breast duct, where 95 per cent of breast cancers originate.
About IMI
IMI is a world leader in predictive medicine. IMI is dedicated to developing rapid, non-invasive tests for the early detection and monitoring of life-threatening diseases, particularly cardiovascular disease and cancer. IMI's lead product is a non-invasive skin test for coronary artery disease. IMI's cancer products in development include ColorectAlert(TM), a screening test for colorectal cancer, LungAlert(TM), a screening test for lung cancer, and a new test for breast cancer. For further information, please visit the company's web site at www.imimedical.com.
This release contains forward-looking statements that reflect the company's current expectation regarding future events. The forward-looking statements involve risk and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly filings.
For further information
Andrew Weir, Director, Communications, (416) 222-3449 x27, aweir@imimedical.com
Richard Land, Karin Oloffson, Jaffoni & Collins Incorporated, (212) 835-8500 or imi@jcir.com
--------------------------------------------------------------------------------
Source: IMI International Medical Innovations Inc. |
